| Ohio First Home Healthcare, Inc | |
| 8075 Reading Road, Suite 202, Cincinnati, Ohio 45237 | |
| (513) 351-1494 | |
| Not Available |
| Name | Ohio First Home Healthcare, Inc |
|---|---|
| Location | 8075 Reading Road, Suite 202, Cincinnati, Ohio |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Home Health Aide |
| Medicare ID | 368370 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 45014, 45203, 45206, 45209, 45211, 45214, 45215, 45225, 45229, 45231, 45237, 45239, 45243 |
| NPI Number | 1295312676 |
| Organization Name | ADVANCE HOME HEALTHCARE, INC. |
| Doing Business As | HOME HEALTHCARE |
| Address | 8075 Reading Rd Ste 203, Cincinnati, OH 45237 |
| Phone Number | 513-928-0197 |
News Archive
A persistent cough and fever have been confirmed as the most prevalent symptoms associated with COVID-19, according to a major review of the scientific literature.
Scientific evidence increasingly links arterial calcification to the presence of nanosized particles so small that some scientists question whether a nanoparticle can live and, if so, play a viable role in causing disease.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models - without adversely affecting the fetus or the mother.
› Verified 4 days ago
| NPI Number | 1477063113 |
| Organization Name | BEACON HOME HEALTH CARE LLC |
| Address | 8075 Reading Rd Ste 201, Cincinnati, OH 45237 |
| Phone Number | 513-834-9991 |
News Archive
A persistent cough and fever have been confirmed as the most prevalent symptoms associated with COVID-19, according to a major review of the scientific literature.
Scientific evidence increasingly links arterial calcification to the presence of nanosized particles so small that some scientists question whether a nanoparticle can live and, if so, play a viable role in causing disease.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models - without adversely affecting the fetus or the mother.
› Verified 4 days ago
| NPI Number | 1558968479 |
| Address | 8075 Reading Rd Ste 105, Cincinnati, OH 45237 |
| Phone Number | 614-815-8069 |
News Archive
A persistent cough and fever have been confirmed as the most prevalent symptoms associated with COVID-19, according to a major review of the scientific literature.
Scientific evidence increasingly links arterial calcification to the presence of nanosized particles so small that some scientists question whether a nanoparticle can live and, if so, play a viable role in causing disease.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models - without adversely affecting the fetus or the mother.
› Verified 4 days ago
| NPI Number | 1801559604 |
| Organization Name | TRINA LOVING CARE HEALTH CARE SERVICE'S |
| Address | 8075 Reading Rd Ste 208b, Cincinnati, OH 45237 |
| Phone Number | 513-407-8132 |
News Archive
A persistent cough and fever have been confirmed as the most prevalent symptoms associated with COVID-19, according to a major review of the scientific literature.
Scientific evidence increasingly links arterial calcification to the presence of nanosized particles so small that some scientists question whether a nanoparticle can live and, if so, play a viable role in causing disease.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models - without adversely affecting the fetus or the mother.
› Verified 4 days ago
| Quality Rating: | Not Available* |
| * The number of patient episodes for this measure is too small to report. | |
News Archive
A persistent cough and fever have been confirmed as the most prevalent symptoms associated with COVID-19, according to a major review of the scientific literature.
Scientific evidence increasingly links arterial calcification to the presence of nanosized particles so small that some scientists question whether a nanoparticle can live and, if so, play a viable role in causing disease.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models - without adversely affecting the fetus or the mother.
› Verified 4 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
A persistent cough and fever have been confirmed as the most prevalent symptoms associated with COVID-19, according to a major review of the scientific literature.
Scientific evidence increasingly links arterial calcification to the presence of nanosized particles so small that some scientists question whether a nanoparticle can live and, if so, play a viable role in causing disease.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models - without adversely affecting the fetus or the mother.
› Verified 4 days ago
The patient survey data of Ohio First Home Healthcare, Inc is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 94 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 85 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 88 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 89 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 75 | 78 |
News Archive
A persistent cough and fever have been confirmed as the most prevalent symptoms associated with COVID-19, according to a major review of the scientific literature.
Scientific evidence increasingly links arterial calcification to the presence of nanosized particles so small that some scientists question whether a nanoparticle can live and, if so, play a viable role in causing disease.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models - without adversely affecting the fetus or the mother.
› Verified 4 days ago
Cincinnati Health Dept - Home Health Program Location: 3101 Burnet Avenue, Cincinnati, Ohio 45229 Ratings: NA Phone: (513) 357-7406 | |
Interim Healthcare Of Cincinnati Location: 8050 Hosbrook, Suite 406, Cincinnati, Ohio 45236 Ratings: Phone: (513) 984-1110 | |
American Mercy Home Care, Llc Location: 4000 Smith Road, Suite 200, Cincinnati, Ohio 45209 Ratings: Phone: (513) 731-4600 | |
Home Healthcare By Black Stone Location: 4700 East Galbraith Road, Suite 300, Cincinnati, Ohio 45236 Ratings: Phone: (513) 924-1370 | |
Children's Hospital Home Health Location: 660 Lincoln Avenue, Cincinnati, Ohio 45206 Ratings: NA Phone: (513) 636-4663 | |
Judson Home Care Location: 2373 Harrison Avenue, Cincinnati, Ohio 45211 Ratings: Phone: (513) 662-5880 |